Alvotech (ALVO)
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - Specialty & Generic
Alvotech
No splits on record
Nothing in ALVO's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $586.32M | $489.68M | $91.43M | $83.03M | $36.77M | $66.62M | $31.92M |
| YoY Growth | 19.7% | 435.6% | 10.1% | 125.8% | -44.8% | 108.7% | - |
| Cost of Revenue | $235.56M | $185.31M | $160.86M | $64.09M | $0 | $0 | $0 |
| Gross Profit | $350.76M | $304.37M | -$69.42M | $18.93M | $36.77M | $66.62M | $31.92M |
| Gross Margin | 59.8% | 62.2% | -75.9% | 22.8% | 100.0% | 100.0% | 100.0% |
| Research and Development | $184.19M | $171.31M | $210.83M | $180.62M | $191.01M | $148.07M | $95.56M |
| Selling, General, and Administrative | $90.95M | $61.45M | $73.04M | $186.74M | $84.13M | $58.91M | $48.57M |
| Other | -$2.58M | $1.96M | $1.57M | -$1.99M | -$2.91M | -$2.83M | -$50.76M |
| Total Operating Expenses | $272.56M | $234.73M | $285.44M | $365.38M | $272.23M | $204.15M | $93.37M |
| Operating Income (EBIT) | $78.21M | $69.64M | -$354.86M | -$346.44M | -$235.46M | -$137.54M | -$61.45M |
| Operating Margin | 13.3% | 14.2% | -388.1% | -417.3% | -640.3% | -206.5% | -192.5% |
| Interest Expense | $149.19M | $157.6M | $134.82M | $91.44M | $112.97M | $97.47M | $95.75M |
| Interest Income | $198.49M | $4.62M | $4.82M | $912K | $19K | $0 | $0 |
| Other Income (Expense) | $58.14M | -$287.21M | -$296.19M | -$205.21M | $86.26M | -$154.23M | -$147.94M |
| Income Before Tax (EBT) | $136.35M | -$217.56M | -$651.05M | -$551.65M | -$149.2M | -$291.77M | -$209.38M |
| Income Tax Expense | $108.43M | $14.3M | -$99.32M | -$38.07M | -$47.69M | -$121.73M | $491K |
| Net Income | $27.92M | -$231.86M | -$551.73M | -$513.58M | -$101.5M | -$170.04M | -$209.88M |
| Net Income Margin | 4.8% | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% | -657.5% |
| Supplementary Data | |||||||
| EPS | 0.10 | -0.87 | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| Diluted EPS | 0.10 | -0.87 | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| Weighted Average OS | 279.19M | 267.92M | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
| EBITDA | $323.39M | -$32.27M | -$493.67M | -$439.8M | -$18.03M | -$177.88M | -$99.02M |
| EBITDA Margin | 55.2% | -6.6% | -539.9% | -529.7% | -49.0% | -267.0% | -310.2% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $172.36M | $51.43M | $11.16M | $66.43M | $17.56M | $31.69M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $172.36M | $51.43M | $11.16M | $66.43M | $17.56M | $31.69M |
| Accounts Receivable | $153.79M | $251.72M | $87.22M | $71.39M | $53.88M | $33.12M |
| Inventory | $220.05M | $127.89M | $74.43M | $71.47M | $39.06M | $9.65M |
| Other Current Assets | $0 | $0 | $0 | $851K | $0 | $5.79M |
| Total Current Assets | $574.01M | $455.02M | $194.84M | $230.74M | $119.82M | $86.16M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $356.4M | $409.74M | $356.58M | $268.1M | $205.33M | $176.97M |
| Goodwill | $12.84M | $11.33M | $12.06M | $11.64M | $12.37M | $13.43M |
| Intangible Assets | $81.83M | $20.62M | $19.08M | $25.65M | $21.51M | $6.33M |
| Long-Term Investments | $122.93M | $22.71M | $18.49M | $48.57M | $55.31M | $56.68M |
| Deferred Tax Assets | $192.21M | $298.36M | $309.81M | $209.5M | $170.42M | $0 |
| Other Long-Term Assets | $146.87M | $3.62M | $39.23M | $34.25M | $13.23M | $134.85M |
| Total Long-Term Assets | $913.08M | $766.38M | $755.25M | $597.71M | $478.16M | $388.26M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.49B | $1.22B | $950.09M | $828.44M | $597.98M | $474.42M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $126.12M | $67.13M | $80.56M | $49.19M | $28.59M | $11.96M |
| Short-Term Debt | $36.92M | $32.7M | $38.02M | $19.92M | $2.77M | $2.5M |
| Current Income Tax Payable | $1.04M | $204K | $925K | $934K | $841K | $0 |
| Current Unearned Revenue | $30.36M | $15.98M | $59.18M | $36.91M | $29.69M | $0 |
| Other Current Liabilities | $9.34M | $6.63M | $34.5M | $17.46M | $0 | $14.63M |
| Total Current Liabilities | $304.08M | $193.4M | $260.95M | $167.29M | $111.84M | $50.98M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $1.26B | $1.04B | $922.13M | $744.65M | $398.14M | $565.4M |
| Long-Term Unearned Revenue | $5.5M | $80.72M | $73.26M | $57.02M | $44.84M | $0 |
| Long-Term Deferred Tax Liabilities | $7.87M | $1.81M | $53K | $309K | $150K | $0 |
| Other Long-Term Liabilities | $53.99M | $210.22M | $520.55M | $388.22M | $63.77M | $621.82M |
| Total Long-Term Liabilities | $1.47B | $1.44B | $1.62B | $1.23B | $621.75M | $1.29B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.77B | $1.63B | $1.88B | $1.39B | $733.59M | $1.34B |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $2.93M | $2.83M | $2.28M | $2.13M | $135K | $73K |
| Retained Earnings | -$2.41B | -$2.44B | -$2.21B | -$1.65B | -$1.14B | -$1.04B |
| Comprehensive Income & Other | $16.68M | $15.05M | $41.38M | $29.14M | $4.67M | $4.97M |
| Other Stockholders' Equity | $2.12B | $2.02B | $1.27B | $1.09B | $1B | $171.71M |
| Total Equity | -$284.49M | -$412.77M | -$932.49M | -$564.42M | -$135.61M | -$867.24M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.49B | $1.22B | $950.09M | $828.44M | $597.98M | $474.42M |
| Supplementary Data | ||||||
| Total Debt | $1.45B | $1.19B | $1.08B | $805.1M | $523.05M | $676.85M |
| Net Debt | $1.28B | $1.14B | $1.06B | $738.67M | $505.5M | $645.16M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | $27.92M | -$231.86M | -$551.73M | -$513.58M | -$101.5M | -$170.04M | -$209.88M |
| Depreciation & Amortization | $37.85M | $31.3M | $24.21M | $20.41M | $18.2M | $16.42M | $14.61M |
| Deferred Income Tax | $108.43M | $14.3M | -$99.32M | -$38.07M | -$47.69M | -$121.73M | $491K |
| Stock-Based Compensation | $17.38M | $7.63M | $18.03M | $10.32M | $0 | $0 | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$6.33M | -$164.24M | -$24.83M | -$13.23M | -$13.53M | $10.1M | -$45M |
| Inventory | -$90.13M | -$49.97M | -$11.3M | -$32.41M | -$29.41M | -$3.25M | -$4.16M |
| Accounts Payable | -$21.18M | $0 | $0 | $0 | $14.32M | $227K | $1.97M |
| Other Working Capital | $0 | -$74.44M | $62.46M | -$2.25M | $21.81M | $25.44M | $33.36M |
| Total Working Capital Change | -$117.64M | -$288.64M | $26.33M | -$47.89M | -$6.81M | $32.52M | -$13.84M |
| Other Non-Cash Items | -$124.14M | $230.44M | $270.29M | $256.42M | -$90.36M | $168.54M | $120.06M |
| Net Cash from Operating | -$50.2M | -$236.84M | -$312.19M | -$312.39M | -$228.17M | -$74.3M | -$88.55M |
| Investing Activities | |||||||
| Capital Expenditures | -$64.47M | -$53.66M | -$33.23M | -$37.88M | -$20.46M | -$7.49M | -$7.2M |
| Acquisitions | -$14.04M | $12M | $0 | $0 | $0 | -$5M | -$5M |
| Purchases of Investments | -$31.66M | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $5.95M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $22.79M | -$13.11M | -$25.66M | -$20.17M | -$4.42M | -$673K |
| Net Cash from Investing | -$104.22M | -$18.87M | -$46.34M | -$63.54M | -$40.63M | -$16.9M | -$12.88M |
| Financing Activities | |||||||
| Debt Repaid | -$202.48M | -$161.48M | -$171.19M | -$307.82M | -$68.97M | -$21.02M | -$85.68M |
| Common Stock Issuance | $78.72M | $150.45M | $136.88M | $9.83M | $185.86M | $34.38M | $30.69M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$10.37M | -$5.13M | -$6.75M | $157.27M | $0 | $0 | $0 |
| Net Cash from Financing | $270.83M | $297.31M | $301.32M | $424.91M | $254.83M | $55.4M | $116.37M |
| Forex Effect | $4.51M | -$1.32M | $1.94M | -$113K | -$161K | $82K | $206K |
| Net Change in Cash | $120.93M | $40.27M | -$55.27M | $48.87M | -$14.13M | -$35.71M | $15.15M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$50.2M | -$236.84M | -$312.19M | -$312.39M | -$228.17M | -$74.3M | -$88.55M |
| Capital Expenditure | -$64.47M | -$57M | -$46.47M | -$49M | -$40.63M | -$11.98M | -$8.05M |
| Free Cash Flow | -$114.67M | -$293.84M | -$358.66M | -$361.39M | -$268.8M | -$86.28M | -$96.6M |
| Cash at Beginning | $51.43M | $11.16M | $66.43M | $17.56M | $31.69M | $67.4M | $52.25M |
| Cash at End | $172.36M | $51.43M | $11.16M | $66.43M | $17.56M | $31.69M | $67.4M |